New drug litfulo tracked in Real-World hair loss study
NCT ID NCT06279221
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study monitors the long-term safety and effectiveness of the drug Litfulo (ritlecitinib) in 487 patients with alopecia areata, a condition causing patchy hair loss. Researchers will track side effects and measure hair regrowth using the SALT score, aiming for a score of 20 or less (meaning minimal scalp hair loss). The study follows patients in real-world settings, not a controlled lab.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan